Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
05 Dezembro 2023 - 8:00AM
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F.
Crowley, Executive Chairman of Amicus Therapeutics, will step down
from the Amicus Board of Directors and assume the role of President
and Chief Executive Officer of BIO, the Biotechnology Innovation
Organization, effective March 4, 2024. Michael Raab, Lead
Independent Director, will become the Chairman of the Amicus Board
of Directors. BIO is based in Washington, DC and is the world’s
largest biotechnology policy and advocacy association, representing
the entire biotechnology industry, with over 1,200 member
organizations worldwide.
Mr. Crowley joined Amicus in 2005 and served as
Chairman and Chief Executive Officer until 2022, when he
transitioned to his current role as Executive Chairman. Under Mr.
Crowley’s leadership, Amicus has grown from a five-person
early-stage start-up to a multi-billion dollar, publicly traded,
commercial organization with two marketed therapies and over 500
employees in 21 countries around the world, treating thousands of
people living with rare and devastating diseases.
“It has been an extraordinary journey and honor
to have built this company and lead the Amicus team of passionate
entrepreneurs,” said John F. Crowley, Executive Chairman of Amicus
Therapeutics, Inc. “Over the past nearly two decades, together we
have faced adversity, achieved much success, and most importantly,
created an enduring legacy of hope for people living with rare
diseases around the world. I have the utmost confidence in Bradley,
the Board, and the entire Amicus team to lead Amicus into the
future as a leading global, patient focused rare disease
biotechnology company.”
“I want to extend our deepest gratitude to John
for building a successful and growing company around a noble and
inspirational mission. I also want to thank John personally for
over two decades of mentorship, partnership, and friendship,” said
Bradley Campbell, President and Chief Executive Officer of Amicus
Therapeutics, Inc. “He has been instrumental in leading Amicus from
a great idea to a global biotechnology company with two approved
therapies for people living with rare diseases. John is the ideal
candidate to lead BIO at such an important time for our industry,
and we all will benefit from his continued visionary
leadership.”
Michael Raab, Amicus’ Lead Independent Director,
said, “On behalf of the Board of Directors and the company, we
thank John for his outstanding leadership and commitment to those
living with rare and devastating diseases. In his new role at BIO
he will continue to expand our shared mission to alleviate human
suffering at a critical time for the Biotechnology Industry. John
and I have worked together for the better part of 20 years, and I
am personally grateful for his pioneering efforts of inventing,
innovating, and advocating on behalf of those in need. Under
Bradley’s leadership, a new era for Amicus begins and is well
positioned to deliver on its promise to patients and shareholders
and I have great confidence in our future.”
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
diseases. With extraordinary patient focus, Amicus Therapeutics is
committed to advancing and expanding a pipeline of cutting-edge,
first- or best-in-class medicines for rare diseases. For more
information please visit the company’s website at www.amicusrx.com,
and follow on Twitter and LinkedIn.
CONTACT:
Investors:Amicus
TherapeuticsAndrew FaughnanVice President, Investor
Relationsafaughnan@amicusrx.com (609) 662-3809
Media:Amicus TherapeuticsDiana
MooreHead of Global Corporate Communicationsdmoore@amicusrx.com
(609) 662-5079
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Amicus Therapeutics (NASDAQ:FOLD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024